

TURCHETTA et al
Appl. No. 10/580,173
January 26, 2009

RECEIVED
CENTRAL FAX CENTER

JAN 26 2009

REMARKS/ARGUMENTS

In response to the Restriction requirement, Applicants hereby elect Group I, namely, claims 34-38 and 47-56, drawn to a form A.

Review of the specification has revealed the presence of certain typographical errors. These have been corrected in the present response. The following comments are offered

1. The chemical name of moxifloxacin contains extraneous brackets and the term "dicyclo" appears instead of "bicyclo". The corrected version is 1-cyclopropyl-7-(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride. This appears in the title, the Abstract, and in paragraphs [0001] and [0002]. Each has been corrected accordingly.
 2. A new Abstract is presented reflecting the above changes and the removal of "p1" before point c).
 3. Paragraph [0012], has been amended to start a new line beginning from the words "a novel hydrate..."
 4. The period appearing after "C" (indicating degrees centigrade) in paragraphs [0005], [0040], [0043]-[0047], [0050] and [0051] has been removed.
- No new matter is entered. Further action is awaited.


TURCHETTA et al
Appl. No. 10/580,173
January 26, 2009

LCM:lff
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Richard
Reg. No. 29,009